What drugs are being tested in NCT06852014?

Interventions in NCT06852014: Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B, Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A.

What condition does NCT06852014 study?

NCT06852014 studies Pancreatic Cancer, Adult, Cephalic Duodenopancreatectomy.

Is NCT06852014 still recruiting?

NCT06852014 is currently recruiting now. Last updated 2 September 2025.

Last reviewed 2025-09-02 · How we verify

NCT06852014

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study

Recruiting now NA Last updated 2 September 2025

What this trial tests

NA trial testing Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B in Pancreatic Cancer, Adult in 20 participants. Currently enrolling.

Timeline

29 May 2025

Primary endpoint
1 June 2026

1 September 2026

Quick facts

Lead sponsor	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	29 May 2025
Primary completion	1 June 2026
Estimated completion	1 September 2026
Sites	1 location across Spain

Drugs / interventions tested

Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B
Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A

Conditions studied

Pancreatic Cancer, Adult — all drugs for Pancreatic Cancer, Adult →
Cephalic Duodenopancreatectomy — all drugs for Cephalic Duodenopancreatectomy →

Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer, Adult or Cephalic Duodenopancreatectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Malnutrition is a common challenge in patients with pancreatic cancer undergoing cephalic pancreaticoduodenectomy (CPD), impacting postoperative recovery and overall prognosis. Nutritional support plays a crucial role in optimising metabolic, inflammatory, and digestive outcomes. This randomised, double-blind, crossover clinical trial aims to evaluate the effects of Peptamen 1.6, a hydrolysed whey protein-based enteral formula, compared to Resource HP/HC, a high-protein and high-calorie polymeric formula, in malnourished or at-risk patients with pancreatic cancer undergoing PD. The study comprises both in vivo and in vitro analyses. The in vivo component will assess the impact of Peptamen 1.6 on digestive tolerance, amino acid absorption, nutritional status, metabolic profile, inflammatory markers, and gut microbiota composition. The in vitro component will utilise human intestinal organoid models to explore how enteral nutrition formulations influence intestinal permeability and metabolism, with a focus on microbiota interactions. Primary outcomes include improvements in metabolic status, assessed through serum biomarkers (albumin, immune markers, intestinal permeability, and myosin profile), inflammatory status via peripheral blood mononuclear cells (PBMCs), and microbiota shifts in faecal samples. Additionally, adherence to treatment, digestive tolerance, and changes in body composition will be monitored using bioelectrical impedance, dynamometry, and functional mobility tests. By elucidating the mechanisms through which different enteral nutrition strategies influence clinical, physiological, and molecular parameters, this study aims to enhance personalised nutritional interventions for patients with pancreatic cancer. The findings could contribute to optimising nutritional support strategies, ultimately improving patient outcomes following CPD.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier.
Brugiapaglia S, Spagnolo F, Curcio C. · · 2025 · cited 1× · PMID 40427617 · DOI 10.3390/biom15050725
Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review.
Terry C, Hall LA, Halle-Smith J, Edwards LA, et al · · 2026 · PMID 42122957 · DOI 10.3390/jcm15093225
Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine.
Lee CJ, Nam Y, Rim YA, Ju JH. · · 2026 · PMID 41656303 · DOI 10.1186/s13287-026-04906-9
Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.
Jagwani S, Musumeci L, Flores L, Mackenzie GG, et al · · 2025 · PMID 41203044 · DOI 10.1016/j.drudis.2025.104528

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer, Adult

Currently open trials in the same condition.

NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
NCT06584227 — Adebrelimab and Chidamide for Pancreatic Cancer · Phase 2 · recruiting
NCT06388967 — Pancreatic Cancer Detection Consortium · recruiting
NCT06822413 — Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis · recruiting
NCT06800469 — Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer · NA · recruiting

Other Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials

Trials by the same sponsor.

NCT06936501 — The Cooling Sensation Safe Deglution Study · NA · recruiting
NCT07192445 — Usability of Graphic Medicine in Psychology Education · NA · completed
NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
NCT06251232 — Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity · Phase 2 · not yet recruiting
NCT06040164 — Oral Endocannabinoids in People With Prediabetes and Diabetes · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06852014 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Last refreshed: 2 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06852014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing